<DOC>
	<DOCNO>NCT01392430</DOCNO>
	<brief_summary>The purpose study compare incidence opportunistic infection HIV-infected patient continue discontinue primary secondary prophylaxis opportunistic infection receive combination antiretroviral therapy achieve undetectable HIV-1 RNA , CD4 cell count less 200 cells/mm3 .</brief_summary>
	<brief_title>Discontinuation Primary Secondary Prophylaxis Opportunistic Infections HIV-infected Patients</brief_title>
	<detailed_description>Currently , combination antiretroviral therapy ( cART ) become standard care treatment HIV infection many part world include Thailand . The benefit cART represent increment CD4 cell count suppression HIV viral load report worldwide . The National Institute Health ( NIH ) , Centers Disease Control Prevention ( CDC ) , HIV Medicine Association Infectious Diseases Society America ( HIVMA/IDSA ) recommend discontinue primary secondary prophylaxis prevention opportunistic infection ( OIs ) HIV-infected adult adolescent receive cART , CD4 cell count increase certain level certain period time . For instance , Pneumocystis jiroveci pneumonia ( PCP ) prophylaxis discontinue patient receive HAART CD4 ≥ 200 cells/mm3 least 3 month ( primary prophylaxis ) least 6 month ( secondary prophylaxis ) , prophylaxis Cryptococcal meningitis , disseminate penicilliosis , cerebral toxoplasmosis , disseminate mycobacterium avium complex discontinue patient receive HAART CD4 ≥ 100 cells/mm3 least 6 month . Our practice follow guideline . However , recently new data show case develop PCP primary secondary prophylaxis discontinuation even CD4 cell count &lt; 200 cells/mm3 . Discontinuation secondary prophylaxis result reduction pill burden may improve HAART adherence , decrease drug-drug interaction , also prevent drug adverse event may happen .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Opportunistic Infections</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<criteria>1 . Age ≥ 18 year old 2. regularly receive highly active antiretroviral therapy ( HAART ) follow 3 . CD4 cell count &lt; 200 cells/mm3 4 . HIV1 RNA &lt; 50 copies/ml receive HAART 5. receive primary secondary prophylaxis opportunistic infection include infection cause Pneumocystis jiroveci , Cryptococcus neoformans , Penicilliosis marneffei , Histoplasma capsulatum , Toxoplasma gondii , Mycobacterium avium complex 6. give write informed consent 1 ) pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Primary prophylaxis</keyword>
	<keyword>Secondary prophylaxis</keyword>
	<keyword>Discontinuation</keyword>
</DOC>